TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24476469

Group type: EXPERIMENTAL
Intervention: Black tea consumption (3 cups per day for 7 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hot water consumption (control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ischaemia-reperfusion protocol after tea consumption
Number of subjects: 20
Study: 23036544

Group type: EXPERIMENTAL
Intervention: Schirmer-I test in Behçet's disease patients
Number of subjects: 89

Group type: COMPARATOR
Intervention: Schirmer-I test in control group
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Break-up time (BUT) test in Behçet's disease patients
Number of subjects: 89

Group type: COMPARATOR
Intervention: Break-up time (BUT) test in control group
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Impression cytology score in Behçet's disease patients
Number of subjects: 89

Group type: COMPARATOR
Intervention: Impression cytology score in control group
Number of subjects: 89
Study: 19581631

Group type: EXPERIMENTAL
Intervention: Stepped-dose efavirenz (200 mg/d on days 1-6, 400 mg/d on days 7-13, 600 mg/d from day 14)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Full-dose efavirenz (600 mg/d from day 1)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Both groups (Stepped-dose and Full-dose)
Number of subjects: 114
Study: 17472846

Group type: EXPERIMENTAL
Intervention: Heparin-coated polyacrylonitrile membrane (AN69ST)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation with calcium-containing dialysate (RCA-Ca3.0)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation with calcium-free dialysate (RCA-Ca0)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation (RCA)
Number of subjects: 33
Study: 16126025

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 654

Group type: COMPARATOR
Intervention: Pravastatin 40 mg
Number of subjects: 654
Study: 12468607

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study: 9796234

Group type: EXPERIMENTAL
Intervention: Vocal response task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manual word response task
Number of subjects: 0
Study: 7648641

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis during perioperation
Number of subjects: 525

Group type: COMPARATOR
Intervention: Routine use of antibiotics as usual (Control)
Number of subjects: 525
Study: 2686258

Group type: EXPERIMENTAL
Intervention: 5 mg isosorbide dinitrate (ISDN)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10 mg isosorbide dinitrate (ISDN)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 20 mg isosorbide dinitrate (ISDN)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 5 mg ISDN + 25 mg gallopamil (G)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 5 mg ISDN + 50 mg gallopamil (G)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 5 mg ISDN + 80 mg propranolol (P)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10 mg ISDN + 25 mg gallopamil (G)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10 mg ISDN + 50 mg gallopamil (G)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10 mg ISDN + 80 mg propranolol (P)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 20 mg ISDN + 25 mg gallopamil (G)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 20 mg ISDN + 50 mg gallopamil (G)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 20 mg ISDN + 80 mg propranolol (P)
Number of subjects: 18
Study: 7388119

Group type: EXPERIMENTAL
Intervention: 100 mg pyridoxine per day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 500 mg pyridoxine per day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 g pyridoxine per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30665392

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous intensity physical activity (MVPA)
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: Steps per day
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: Sitting time
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: Standing time
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: MVPA and sitting time by sex
Number of subjects: 1252
Study: 27913066

Group type: EXPERIMENTAL
Intervention: Betamethasone‐17‐valerate cream
Number of subjects: 202

Group type: COMPARATOR
Intervention: Essex® cream (moisturizer)
Number of subjects: 202
Study: 25338266

Group type: EXPERIMENTAL
Intervention: Occupation-based after-school program (experimental group, n = 25), attended two times a week.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (n = 29), did not participate in an after-school program.
Number of subjects: 54
Study: 24402587

Group type: EXPERIMENTAL
Intervention: Same-day synthetic osmotic dilators
Number of subjects: 72

Group type: COMPARATOR
Intervention: Overnight Laminaria
Number of subjects: 72
Study: 22676330

Group type: EXPERIMENTAL
Intervention: FREMS and topical treatment (Group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Topical treatment alone (Group B)
Number of subjects: 20
Study: 20393636

Group type: EXPERIMENTAL
Intervention: Fesoterodine fumarate
Number of subjects: 0
Study: 18778138

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy treatment for alcohol dependence
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Abstinence goal
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Controlled drinking goal
Number of subjects: 57

Group type: COMPARATOR
Intervention: Traditional measures of outcome
Number of subjects: 57
Study: 15641125

Group type: EXPERIMENTAL
Intervention: Methylphenidate (5 mg/day increasing to 20 mg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sertraline (25 mg/day increasing to 100 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11991367

Group type: EXPERIMENTAL
Intervention: VVIR pacing
Number of subjects: 18

Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 18
Study: 9915366

Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (ITB) 50 microg bolus injection followed by continuous infusion of 302 microg per day
Number of subjects: 17
Study: 7768573

Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion
Number of subjects: 8
Study: 2333596

Group type: EXPERIMENTAL
Intervention: Excision of the nail edge and chemical ablation of germinal matrix edge with 70% aqueous phenol (Group A)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Surgical excision of nail edges and germinal matrix edges (Group B)
Number of subjects: 66
Study: 7035598

Group type: EXPERIMENTAL
Intervention: High doses of stilboestrol and ethisterone therapy during pregnancy
Number of subjects: 136

Group type: COMPARATOR
Intervention: Inactive tablet (control)
Number of subjects: 136
Study: 30227765

Group type: EXPERIMENTAL
Intervention: Tai chi intervention designed to decrease cardiometabolic risk factors in women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tailored guided imagery intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mindful physical activity intervention (yoga)
Number of subjects: 0
Study: 28470821

Group type: EXPERIMENTAL
Intervention: Foster care intervention
Number of subjects: 12

Group type: COMPARATOR
Intervention: Institutionalization
Number of subjects: 12
Study: 25928298

Group type: EXPERIMENTAL
Intervention: Targeted marketing messages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard clinical information
Number of subjects: 0
Study: 23578678

Group type: EXPERIMENTAL
Intervention: Iterative Reconstruction (IR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Filtered Back Projection (FBP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lower dose CTP (80 mAs)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Standard dose CTP (100 mAs)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both IR and FBP algorithms
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both algorithms
Number of subjects: 40
Study: 21250993

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control condition (placebo)
Number of subjects: 34
Study: 19967603

Group type: EXPERIMENTAL
Intervention: Hot/cold water immersion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 20

Group type: COMPARATOR
Intervention: No recovery (control)
Number of subjects: 20
Study: 17896734

Group type: EXPERIMENTAL
Intervention: Posters in paediatricians' waiting area during intervention week
Number of subjects: 808

Group type: COMPARATOR
Intervention: No posters in paediatricians' waiting area during control week
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Overall intervention (posters)
Number of subjects: 808
Study: 14749224

Group type: EXPERIMENTAL
Intervention: Moderate-fat diet (33% of energy)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Low-fat diet (18% of energy)
Number of subjects: 53
Study: 11337737

Group type: EXPERIMENTAL
Intervention: Mechanical abdominal wall lift (AWL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of AWL with low-pressure pneumoperitoneum (3 to 4 mm Hg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional pneumoperitoneum (12 mm Hg)
Number of subjects: 0
Study: 9429053

Group type: EXPERIMENTAL
Intervention: self‐administered subcutaneous recombinant human erythropoietin (rhEPO) at a dose of 60 U.kg‐1 BW three times a week and oral iron treatment (ferrofumarate)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: self‐administered subcutaneous recombinant human erythropoietin (rhEPO) and oral iron treatment
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: self‐administered subcutaneous recombinant human erythropoietin (rhEPO)
Number of subjects: 32
Study: 7939760

Group type: EXPERIMENTAL
Intervention: 135 mg/m2 given as a single dose over 1 hour
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 135 mg/m2 given in divided hourly daily doses for 3 days
Number of subjects: 56

Group type: COMPARATOR
Intervention: Both schedules of paclitaxel
Number of subjects: 56
Study: 3282004

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dothiepin
Number of subjects: 0
Study: 31983186

Group type: EXPERIMENTAL
Intervention: Prostate cancer educational program
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 154
Study: 29117275

Group type: EXPERIMENTAL
Intervention: CCBT alone
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: CCBT+ISG
Number of subjects: 704

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 704
Study: 27149404

Group type: EXPERIMENTAL
Intervention: 25-gauge core biopsy needle
Number of subjects: 56

Group type: COMPARATOR
Intervention: 22-gauge core biopsy needle
Number of subjects: 56
Study: 26214630

Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy with 4 cycles of carboplatin and etoposide followed by conformal 3-dimensional (3D) radiotherapy (RT)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Concurrent chemotherapy with cisplatin and etoposide and conformal RT, followed by two cycles of consolidation chemotherapy with carboplatin and etoposide
Number of subjects: 85
Study: 23439617

Group type: EXPERIMENTAL
Intervention: State-of-the-art methodology for clinical trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rigorous approach to menstrual trial data collection
Number of subjects: 0
Study: 19880208

Group type: EXPERIMENTAL
Intervention: Resistance training combined with antioxidant supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no intervention mentioned)
Number of subjects: 0
Study: 19011437

Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bilastine 40 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bilastine 80 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hydroxyzine 25 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15834341

Group type: EXPERIMENTAL
Intervention: Oxford Cobbometer
Number of subjects: 24
Study: 12430112

Group type: EXPERIMENTAL
Intervention: Fentanyl 10 micro g added to 0.5% hyperbaric ropivacaine 18 mg
Number of subjects: 59

Group type: COMPARATOR
Intervention: Normal saline 0.2 mL added to 0.5% hyperbaric ropivacaine 18 mg
Number of subjects: 59
Study: 10355002

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (INR: 2.0‐3.0)
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Combination of acetylsalicylic acid (30-325 mg/day) plus dipyridamole (400 mg daily)
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid only (30-325 mg/day)
Number of subjects: 4500
Study: 8942891

Group type: EXPERIMENTAL
Intervention: Adjunctive subconjunctival mitomycin C (MMC)
Number of subjects: 174

Group type: COMPARATOR
Intervention: No adjunctive mitomycin C (Control)
Number of subjects: 174
Study: 1760462

Group type: EXPERIMENTAL
Intervention: EMG biofeedback
Number of subjects: 12

Group type: COMPARATOR
Intervention: Relaxation training and graded neck exercises (RGP)
Number of subjects: 12
Study: 7036396

Group type: EXPERIMENTAL
Intervention: Flexible endoscopic sclerotherapy using 5% sodium morrhuate
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Esophageal transection/reanastomosis employing the EEA Auto Suture stapling instrument
Number of subjects: 13

Group type: COMPARATOR
Intervention: Portacaval shunt
Number of subjects: 13
Study: 31780589

Group type: EXPERIMENTAL
Intervention: Clinically-supervised gradual reduction of antipsychotic medication leading to discontinuation when possible
Number of subjects: 134

Group type: COMPARATOR
Intervention: Maintenance treatment with antipsychotic medication
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Clinically-supervised gradual reduction of antipsychotic medication
Number of subjects: 134
Study: 29392287

Group type: EXPERIMENTAL
Intervention: Noninvasive keratograph breakup time (NIKBUT)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Fluorescein breakup time (TBUT)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: NIKBUT
Number of subjects: 74

Group type: COMPARATOR
Intervention: TBUT
Number of subjects: 74
Study: 27684802

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) at 4.33 μg/kg combined with sufentanil (SUF) at 3.0 μg/kg via PCIA
Number of subjects: 25
Study: 23839729

Group type: EXPERIMENTAL
Intervention: Increased training volume from 4.9 to 18 h.wk-1
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Increased training volume
Number of subjects: 6
Study: 22497754

Group type: EXPERIMENTAL
Intervention: Lamotrigine extended-release (LTG XR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pragmatic ITT (P‐ITT) methodology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Last observation carried forward (LOCF) methodology
Number of subjects: 0
Study: 19439743

Group type: EXPERIMENTAL
Intervention: Scorpion-specific F(ab')(2) antivenom
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 17069546

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12582834

Group type: COMPARATOR
Intervention: Prazosin (alpha(1)-adrenergic antagonist), single oral dose
Number of subjects: 0
Study: 11187913

Group type: EXPERIMENTAL
Intervention: Therapy based on the Berlin‐Frankfurt‐Münster 76/79 study
Number of subjects: 16000

Group type: EXPERIMENTAL
Intervention: Delayed intensification (DI)
Number of subjects: 16000

Group type: EXPERIMENTAL
Intervention: Maintenance intrathecal methotrexate
Number of subjects: 16000

Group type: EXPERIMENTAL
Intervention: One vs no DI phase for lower risk patients
Number of subjects: 16000

Group type: EXPERIMENTAL
Intervention: Two vs one DI phase for intermediate risk patients
Number of subjects: 16000

Group type: EXPERIMENTAL
Intervention: CCG 'augmented regimen' for higher risk patients with a slow day 7 marrow response
Number of subjects: 16000

Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate
Number of subjects: 16000

Group type: EXPERIMENTAL
Intervention: Dexamethasone in place of prednisone in induction and maintenance
Number of subjects: 16000

Group type: EXPERIMENTAL
Intervention: Dexamethasone in DI
Number of subjects: 16000

Group type: EXPERIMENTAL
Intervention: 10-year EFS
Number of subjects: 16000

Group type: EXPERIMENTAL
Intervention: Five-year cumulative rates of isolated CNS relapses
Number of subjects: 16000
Study: 8797480

Group type: EXPERIMENTAL
Intervention: Cabergoline (CBG)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Bromocriptine (BCR)
Number of subjects: 44
Study: 1625101

Group type: EXPERIMENTAL
Intervention: rHuEPO, 400 IU/kg three times a week plus iron, 20 mg/wk intravenously
Number of subjects: 22

Group type: COMPARATOR
Intervention: No rHuEPO and no iron
Number of subjects: 22
Study: 6387184

Group type: EXPERIMENTAL
Intervention: 100 mg trimethoprim (20 patients)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (20 patients)
Number of subjects: 40
Study: 31733760

Group type: EXPERIMENTAL
Intervention: High intensity hatha yoga exercises (HIY)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no change in exercise behavior)
Number of subjects: 44
Study: 28980368

Group type: EXPERIMENTAL
Intervention: Target dose enalapril (20 mg/day)
Number of subjects: 2569

Group type: EXPERIMENTAL
Intervention: Below-target dose enalapril (5-10 mg/day)
Number of subjects: 2569

Group type: COMPARATOR
Intervention: Target dose placebo (20 mg/day)
Number of subjects: 2569

Group type: COMPARATOR
Intervention: Below-target dose placebo (5-10 mg/day)
Number of subjects: 2569

Group type: EXPERIMENTAL
Intervention: Target dose enalapril vs. below-target dose enalapril
Number of subjects: 2569
Study: 27208972

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) treatment
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 14
Study: 25294957

Group type: EXPERIMENTAL
Intervention: Eccentric training program (6 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 20
Study: 22767583

Group type: EXPERIMENTAL
Intervention: 30 Gy extended-field radiotherapy (EF-RT)
Number of subjects: 1204

Group type: COMPARATOR
Intervention: 30 Gy involved-field radiotherapy (IF-RT)
Number of subjects: 1204
Study: 20589459

Group type: EXPERIMENTAL
Intervention: Poractant (curosurf)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Beractant (Survanta)
Number of subjects: 150
Study: 17493477

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 1024
Study: 16125491

Group type: EXPERIMENTAL
Intervention: 17-beta-estradiol eluting stent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phosphorylcholine-coated stent
Number of subjects: 0
Study: 11959616

Group type: EXPERIMENTAL
Intervention: Grapefruit juice with praziquantel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water treatment with praziquantel
Number of subjects: 0
Study: 10096460

Group type: COMPARATOR
Intervention: naproxen
Number of subjects: 0

Group type: COMPARATOR
Intervention: dydrogesterone
Number of subjects: 0

Group type: COMPARATOR
Intervention: danazol
Number of subjects: 0

Group type: COMPARATOR
Intervention: leuprolide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: laser laparoscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: oral contraceptives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zoladex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: gestrinone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: nafarelin
Number of subjects: 0
Study: 7503194

Group type: EXPERIMENTAL
Intervention: Oral terbutaline (n = 50)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Oral terbutaline (n = 41)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control (no oral terbutaline, n = 53)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control (no oral terbutaline, n = 40)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Oral terbutaline
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control
Number of subjects: 184
Study: 2188763

Group type: EXPERIMENTAL
Intervention: 30 mg APD intravenously
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control saline infusion
Number of subjects: 10
Study: 6999345

Group type: EXPERIMENTAL
Intervention: Clofibate
Number of subjects: 3892

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3892

Group type: EXPERIMENTAL
Intervention: Clofibate (Good Adherers)
Number of subjects: 3892

Group type: EXPERIMENTAL
Intervention: Clofibate (Poor Adherers)
Number of subjects: 3892

Group type: COMPARATOR
Intervention: Placebo (Good Adherers)
Number of subjects: 3892

Group type: COMPARATOR
Intervention: Placebo (Poor Adherers)
Number of subjects: 3892
Study: 30758294

Group type: EXPERIMENTAL
Intervention: Immediate-use group (iApp)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Delayed use group (dApp)
Number of subjects: 97
Study: 29038221

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25563826

Group type: COMPARATOR
Intervention: Furosemide (0.2 mg/kg/h, up to 0.8 mg/kg/h)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Ethacrynic Acid (0.2 mg/kg/h, up to 0.8 mg/kg/h)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Ethacrynic Acid
Number of subjects: 74
Study: 23975856

Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) shrinkage treatment
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional surgical treatment (Control)
Number of subjects: 38
Study: 21120480

Group type: EXPERIMENTAL
Intervention: Cediranib administered in fed state
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cediranib 30 mg/day (fixed-dose)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cediranib (general)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cediranib administered in fasted state
Number of subjects: 60
Study: 19434533

Group type: EXPERIMENTAL
Intervention: Postoperative intraperitoneal chemotherapy combined with systemic chemotherapy
Number of subjects: 332

Group type: COMPARATOR
Intervention: Systemic chemotherapy alone
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy regimen with Oxaliplatin
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy regimen with Cisplatin
Number of subjects: 332